| 股票 | 标签 | 富途行业 | PE | PB | 股息率 | 分红率 | 毛利率 | ROE | 固定资产 | 负债率 | OCF/市值 | 营收增速 | 利润增速 | 近60日 | YTD | 近一年 | 距52周高 | 市值亿 ▾ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 赛默飞世尔 TMO | 中性 | 诊断与研究 | 33.0 | 4.31 | 0.3% | 10% | 41% | 13% | 8% | 52% | 4.0% | +4% | +6% | +28% | +6% | +26% | 95% | 2269 |
| 丹纳赫 DHR | 中性 | 诊断与研究 | 36.9 | 2.78 | 0.7% | 25% | 59% | 7% | 6% | 37% | 4.5% | +3% | -7% | +13% | -9% | +5% | 86% | 1460 |
| Natera NTRA | 亏损或困境 | 诊断与研究 | -243.1 | 25.97 | 0.0% | — | 65% | -14% | 10% | 29% | 0.5% | +36% | -9% | +52% | +43% | +96% | 96% | 473 |
| 艾昆纬 IQV | 中性 | 诊断与研究 | 33.3 | 7.14 | 0.0% | 0% | 33% | 22% | 3% | 78% | 6.4% | +6% | -1% | +47% | +19% | +43% | 98% | 441 |
| 安捷伦科技 A | 定价权·品牌 | 诊断与研究 | 29.8 | 5.78 | 0.7% | 20% | 52% | 21% | 13% | 47% | 3.8% | +7% | +1% | +15% | +12% | +19% | 92% | 425 |
| 爱德士 IDXX | 中性 | 诊断与研究 | 37.6 | 26.16 | 0.0% | 0% | 62% | 66% | 26% | 52% | 3.3% | +10% | +19% | -4% | -21% | -18% | 70% | 422 |
| 沃特世 WAT | 纯久期 | 诊断与研究 | 103.6 | 2.65 | 0.0% | 0% | 59% | 29% | 16% | 50% | 1.4% | +7% | +1% | +13% | +8% | +32% | 96% | 402 |
| Illumina ILMN | 成长兑现 | 诊断与研究 | 40.7 | 11.61 | 0.0% | 0% | 66% | 33% | 19% | 59% | 3.3% | -1% | +170% | +34% | +66% | +122% | 94% | 330 |
| 梅特勒-托利多 MTD | 中性 | 诊断与研究 | 30.3 | 2101.97 | 0.0% | 0% | 59% | 0% | 22% | 101% | 3.6% | +4% | +1% | +19% | -4% | +2% | 88% | 270 |
| 徕博科 LH | 中性 | 诊断与研究 | 27.0 | 3.08 | 0.9% | 24% | 29% | 10% | 17% | 53% | 6.2% | +7% | +18% | +22% | +31% | +19% | 96% | 265 |
| 奎斯特诊疗 DGX | 中性 | 诊断与研究 | 25.2 | 3.48 | 1.0% | 26% | 33% | 14% | 20% | 55% | 7.3% | +12% | +14% | +17% | +38% | +32% | 96% | 262 |
| Guardant Health GH | 亏损或困境 | 诊断与研究 | -46.0 | -97.18 | 0.0% | — | 64% | 0% | 14% | 105% | -0.9% | +33% | +5% | +24% | +58% | +168% | 91% | 217 |
| Medpace MEDP | 中性 | 诊断与研究 | 34.7 | 38.04 | 0.0% | 0% | 30% | 70% | 9% | 77% | 4.6% | +20% | +12% | +27% | +5% | +20% | 87% | 165 |
| Revvity RVTY | 纯久期 | 诊断与研究 | 62.6 | 2.01 | 0.2% | 14% | 55% | 3% | 5% | 40% | 4.3% | +4% | -11% | +29% | +35% | +51% | 98% | 145 |
| 查尔斯河实验室 CRL | 亏损或困境 | 诊断与研究 | -60.1 | 4.85 | 0.0% | — | 33% | -4% | 24% | 55% | 4.2% | -1% | -662% | +55% | +45% | +78% | 95% | 138 |
| Icon PLC ICLR | 纯久期 | 诊断与研究 | 253.6 | 1.36 | 0.0% | 0% | 26% | 2% | 4% | 44% | 8.4% | +1% | -69% | +14% | -10% | -7% | 81% | 127 |
| 快而精医药 QGEN | 成长兑现 | 诊断与研究 | 22.1 | 2.67 | 0.8% | 18% | 62% | 12% | 12% | 40% | 7.3% | +6% | +408% | +18% | -3% | -8% | 76% | 90 |
| RadNet RDNT | 重资产陷阱 | 诊断与研究 | -283.5 | 5.29 | 0.0% | — | 12% | -2% | 34% | 64% | 5.3% | +12% | -56% | +27% | +3% | +2% | 86% | 58 |
| Sotera Health Company SHC | 定价权·品牌 | 诊断与研究 | 33.2 | 8.10 | 0.0% | 0% | 56% | 15% | 27% | 81% | 5.4% | +6% | +76% | +16% | +7% | +19% | 95% | 54 |
| BillionToOne BLLN | 纯久期 | 诊断与研究 | 103.4 | 8.74 | 0.0% | 0% | 68% | 3% | 9% | 24% | 1.0% | +100% | +118% | +0% | +21% | +66% | 66% | 47 |
| Adaptive Biotechnologies ADPT | 亏损或困境 | 诊断与研究 | -60.7 | 27.13 | 0.0% | — | 74% | -28% | 17% | 56% | -0.5% | +55% | +63% | +42% | +50% | +94% | 90% | 39 |
| Grail GRAL | 亏损或困境 | 诊断与研究 | -8.3 | 1.41 | 0.0% | — | -42% | -16% | 3% | 12% | -8.2% | +17% | +80% | +37% | -6% | +110% | 68% | 36 |
| Veracyte VCYT | 成长兑现 | 诊断与研究 | 30.4 | 2.46 | 0.0% | 0% | 70% | 5% | 4% | 7% | 5.2% | +16% | +175% | -12% | +1% | +31% | 70% | 34 |
| CareDx CDNA | 中性 | 诊断与研究 | 24.5 | 6.18 | 0.0% | 0% | 68% | -6% | 10% | 27% | 3.6% | +14% | -141% | +117% | +170% | +281% | 95% | 26 |
| GeneDx Holdings WGS | 亏损或困境 | 诊断与研究 | -23.8 | 10.50 | 0.0% | — | 70% | -8% | 9% | 41% | -1.9% | +40% | +60% | +58% | -34% | -34% | 50% | 26 |
| NeoGenomics NEO | 亏损或困境 | 诊断与研究 | -44.6 | 2.84 | 0.0% | — | 43% | -12% | 12% | 38% | 1.0% | +10% | -37% | +54% | +48% | +119% | 88% | 22 |
| Personalis PSNL | 亏损或困境 | 诊断与研究 | -15.8 | 7.81 | 0.0% | — | 23% | -35% | 19% | 22% | -5.0% | -18% | +0% | +79% | +116% | +223% | 91% | 18 |
| Freenome FRNM | 亏损或困境 | 诊断与研究 | -6.8 | -1.26 | 0.0% | — | 94% | 0% | 29% | 349% | -6.3% | +955% | +20% | +45% | +25% | +54% | 95% | 18 |
| Opko健康 OPK | 亏损或困境 | 诊断与研究 | -23.4 | 1.03 | 0.0% | — | 34% | -17% | 6% | 34% | -10.1% | -15% | -324% | +14% | +30% | +16% | 95% | 12 |
| Castle Biosciences CSTL | 亏损或困境 | 诊断与研究 | -51.4 | 2.14 | 0.0% | — | 79% | -5% | 9% | 19% | 4.2% | +4% | -232% | +56% | -15% | +37% | 74% | 10 |
| Fulgent Genetics FLGT | 亏损或困境 | 诊断与研究 | -7.0 | 0.54 | 0.0% | — | 41% | -5% | 7% | 9% | -15.4% | +14% | -41% | +4% | -25% | -11% | 64% | 5 |
| 万基遗传 MYGN | 亏损或困境 | 诊断与研究 | -2.7 | 1.00 | 0.0% | — | 70% | -68% | 15% | 48% | 2.5% | -2% | -187% | -28% | -48% | -54% | 37% | 3 |
| Biodesix BDSX | 亏损或困境 | 诊断与研究 | -8.4 | 30.20 | 0.0% | — | 81% | -383% | 21% | 103% | -7.2% | +24% | +18% | +74% | +285% | +203% | 84% | 3 |
| Exagen XGN | 亏损或困境 | 诊断与研究 | -9.2 | 15.04 | 0.0% | — | 58% | -148% | 14% | 70% | -3.5% | +20% | -32% | +81% | +25% | -23% | 62% | 2 |
| Insight Molecular Diagnostics IMDX | 亏损或困境 | 诊断与研究 | -2.7 | -6.34 | 0.0% | — | 57% | 0% | 27% | 222% | -20.0% | +116% | +17% | -28% | -45% | +66% | 48% | 1 |
| Quantum Cyber QUCY | 亏损或困境 | 诊断与研究 | -1.0 | 6.57 | 0.0% | — | 73% | -488% | 16% | 88% | -10.7% | -40% | +25% | -17% | +42% | -3% | 32% | 1 |
| 燃石医学 BNR | 亏损或困境 | 诊断与研究 | -14.4 | 1.65 | 0.0% | — | 75% | -10% | 34% | 35% | -4.0% | +9% | +83% | +44% | -40% | +32% | 29% | 1 |
| MDxHealth MDXH | 亏损或困境 | 诊断与研究 | -1.0 | -2.35 | 0.0% | — | 64% | -2440% | 8% | 108% | -7.4% | +20% | +12% | +36% | -79% | -79% | 14% | 1 |
| Precipio PRPO | 纯久期 | 诊断与研究 | -44.2 | 3.32 | 0.0% | — | 44% | -3% | 12% | 32% | 2.2% | +30% | +92% | +22% | +19% | +30% | 82% | 0 |
| Advanced Biomed ADVB | 中性 | 诊断与研究 | 2.4 | 1.67 | 0.0% | 0% | — | -127% | — | 47% | -18.9% | +0% | -17% | +140% | +60% | +8% | 38% | 0 |
| ENDRA Life Sciences NDRA | 亏损或困境 | 诊断与研究 | -1.0 | 1.44 | 0.0% | — | — | -292% | — | 41% | -53.2% | +0% | +39% | +44% | +34% | +47% | 61% | 0 |
| bioAffinity Technologies BIAF | 亏损或困境 | 诊断与研究 | -11.3 | 2.40 | 0.0% | — | 30% | -302% | 12% | 34% | -126.8% | -34% | -65% | -33% | -14% | -86% | 8% | 0 |
| XWELL Inc XWEL | 亏损或困境 | 诊断与研究 | -0.2 | -4.52 | 0.0% | — | 26% | 0% | 24% | 212% | -134.4% | -14% | +2% | -17% | +112% | -10% | 44% | 0 |
| iSpecimen ISPC | 亏损或困境 | 诊断与研究 | -0.0 | 2.23 | 0.0% | — | 1% | -328% | 4% | 68% | -180.6% | -79% | +16% | -42% | -85% | -95% | 1% | 0 |
点表头排序。市值单位亿美元;财务为最近年报(futu 筛选器);分红率 = 股息率 × PE;OCF/市值 = 经营现金流 ÷ 市值(无 FCF);距52周高 = 现价 / 52 周最高。